Distribution date: 19 October 2020 | Final date for Comment: 18 December 2020

This Draft Uganda Standard specifies the requirements, test methods and sampling of acrylic yarn to be used for machine weaving, hand weaving, hand knitting and machine knitting.

Products Covered: Acrylic yarn

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

Resolution – RDC number 346, 1 March 2020 – previously notified through G/TBT/N/BRA/984 – which establishes extraordinary and temporary criteria and procedure for Good Manufacture Practice Guidelines for market authorization and post-market registration amendments of Active Pharmaceutical Ingredients, medicines, and healthcare products due to the international public health emergency of the new coronavirus (Covid-19), was changed by the Resolution – RDC number 419, 1 September 2020.

Products Covered: HS Code(s): 29, 2936, 2937, 2941, 30, 3001, 3002, 3003, 3004, 3005, 3006. (pharmaceutical products, active pharmaceutical ingredients, and healthcare products)

Regulation Type: Addendum to Regular Notification

Distribution date: 19 October 2020 | Final date for Comment: 18 December 2020

This Draft Uganda Standard specifies requirements for woven and knit flat and fitted bed sheets and pillowcases meant for institutional and household purposes. This standard is not applicable to 100% cotton bed sheets and similar products used in hospitals.

Products Covered: Bedsheets, Pillowcases

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 18 December 2020

This Draft Uganda Standard specifies requirements for woven and knit flat and fitted bed sheets and pillowcases meant for institutional and household purposes. This standard is not applicable to 100% cotton bed sheets and similar products used in hospitals.

Products Covered: Bedsheets, Pillowcases

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

This Normative Instruction establishes the inclusion of a declaration in the label of medical devices informing the existence of a new formula changing its composition.

Products Covered: Dried glands and other organs for organo-therapeutic uses, whether or not powdered; extracts of glands or other organs or their secretions, for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, n.e.s. (HS code(s): 3001); Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar products (HS code(s): 3002); Medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3003); Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3004); Pharmaceutical preparations and products of subheading Nos 3006.10.10 to 3006.60.90 (HS code(s): 3006)

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

This Normative Instruction establishes the inclusion of a declaration in the label of medical devices informing the existence of a new formula changing its composition.

Products Covered: Dried glands and other organs for organo-therapeutic uses, whether or not powdered; extracts of glands or other organs or their secretions, for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, n.e.s. (HS code(s): 3001); Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar products (HS code(s): 3002); Medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3003); Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3004); Pharmaceutical preparations and products of subheading Nos 3006.10.10 to 3006.60.90 (HS code(s): 3006)

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

This Normative Instruction establishes the inclusion of a declaration in the label of low risk notified medicines products, herbal medicinal products, and cannabis-based medicine informing the existence of a new formula changing its composition.

Products Covered: Antibiotics (HS code(s): 2941); Medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3003); Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3004); Wadding, gauze, bandages and the like, e.g. dressings, adhesive plasters, poultices, impregnated or covered with pharmaceutical substances or put up for retail sale for medical, surgical, dental or veterinary purposes (HS code(s): 3005); Pharmaceutical preparations and products of subheading Nos 3006.10.10 to 3006.60.90 (HS code(s): 3006); True hemp "Cannabis sativa L.", raw or processed, but not spun; tow and waste of true hemp, incl. yarn waste and garnetted stock (HS code(s): 5302); Pharmaceutics (ICS code(s): 11.120)

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

This Normative Instruction establishes the inclusion of a declaration in the label of low risk notified medicines products, herbal medicinal products, and cannabis-based medicine informing the existence of a new formula changing its composition.

Products Covered: Antibiotics (HS code(s): 2941); Medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3003); Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, in measured doses or put up for retail sale (excl. goods of heading 3002, 3005 or 3006) (HS code(s): 3004); Wadding, gauze, bandages and the like, e.g. dressings, adhesive plasters, poultices, impregnated or covered with pharmaceutical substances or put up for retail sale for medical, surgical, dental or veterinary purposes (HS code(s): 3005); Pharmaceutical preparations and products of subheading Nos 3006.10.10 to 3006.60.90 (HS code(s): 3006); True hemp "Cannabis sativa L.", raw or processed, but not spun; tow and waste of true hemp, incl. yarn waste and garnetted stock (HS code(s): 5302); Pharmaceutics (ICS code(s): 11.120)

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

This Normative Instruction establishes the inclusion of a declaration in the label of personal hygiene products (including disposable products), cosmetics, and perfumes informing the existence of a new formula changing its composition.

Products Covered: HS 340130; 9619

Regulation Type: Regular notification

Distribution date: 19 October 2020 | Final date for Comment: 15 May 2025

This Normative Instruction establishes the inclusion of a declaration in the label of personal hygiene products (including disposable products), cosmetics, and perfumes informing the existence of a new formula changing its composition.

Products Covered: HS 340130; 9619

Regulation Type: Regular notification